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Yolk sac tumorChemotherapy relatedmyocardial infarction is rare but can be life-threatening. Herein, we present a 24-year-old
yolk-sac tumor patient admitted to the emergency departmentwith acutemyocardial infarction. The patient had
received the third cycle of combined chemotherapywith bleomycin, etoposide and cisplatin for days ago. Electro-
cardiogram showed acute anterior myocardial infarction and the patient was treated successfully with tissue
plasminogen activator. To the best of our knowledge, this is the ﬁrst case which was treated with ﬁbrinolytic
therapy in a patient with chemotherapy related myocardial infarction in literature. Cancer chemotherapy may
be complicated by acute coronary events and physicians should assess cautiously patients according to their
coronary symptoms and risk factors before and during chemotherapy.
© 2015 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Testicular cancer is one of the most common solid tumors in young
adults. However, yolk-sac tumor (YST) is rare in this population.1 The
mainstay therapy of YST is combined chemotherapy with cisplatin,
etoposide and bleomycin (BEP) after testicular surgery. The main side
effects of the chemotherapy regimen are renal dysfunction, peripheral
neuropathy, pulmonary ﬁbrosis, infertility, secondary leukemia and
vascular toxicity.2 Vascular toxicity is usually venous, however arterial
or coronary events due to chemotherapy are seen rare. Herein, we
present a young patient with myocardial infarction (MI) during BEP
chemotherapy for YST.
Case Report
A 24-year-old male patient was admitted to the urology clinic with
pain and swelling in the right testicle. Right orchiectomywas performed
on patients upon detection ofmass lesion. The pathology report showed
a nonseminomatous germ cell tumor (yolk sac tumor subgroup) and
four courses of combined chemotherapy with BEP were planned. The
patient received chemotherapy every twenty-one days in the doses of
100 mg/m2 cisplatin and 100 mg/m2 etoposide on the ﬁrst 5 days and
30 mg bleomycin on days 1, 8, and 15 of each course.
On the fourth day of the third chemotherapy course, the patient was
admitted to the emergency department with severe chest pain. Therepartment of Cardiology, 27310
3603928.
diovascular Academy.
y. Production and hosting by Elsevwere no pathologic ﬁndings in his physical examination. Arterial blood
pressure was 120/80 mmHg and the heart rate was 95 beats/min. The
Electrocardiogram (ECG) showed ST segment elevations in anterior
derivations (Fig. 1). The patient was immediately taken to intensive
care unit because the hospital did not contain interventional laboratory.
300 mg aspirin, 300mg clopidogrel and 5000 units intravenous heparin
were given as initial treatment. The patient was administered intrave-
nous with 100 mg tissue plasminogen activator in 90 min, concurrently
1000 units/h heparin. Resolution of ST-segment elevation was seen on
ECG and patient's chest pain disappeared at the end of ﬁbrinolytic
therapy. At the forthminute of admission to hospital, the creatine kinase
value was 1527 IU/l and creatine kinase-MB 187 IU/l. The troponin-T
was positive. The other hematologic and biochemical laboratory data
was normal. The patient was non-smoker and had no cardiovascular
risk factor. The patient was transferred to catheter laboratory to clarify
the lesion was atherosclerotic plaque or vasospasm, and coronary
angiography revealed normal coronary arteries (Fig. 2). There was not
any segmental wall motion anomaly on echocardiogram. The patient
was discharged with treatment of 300 mg/day aspirin and 75 mg/day
clopidogrel and called to the control after 1 month.
Discussion
Acute myocardial infarction is commonly caused by coronary
atherosclerosis. Most of the patients have cardiovascular risk factors
such as, hypertension, diabetes, tobacco use, dyslipidemia, obesity,
age, gender and family history. Rarely, intracardiac thrombus can
cause myocardial infarction in structural heart disease (prosthetic
heart valve, mitral stenosis etc.). In our case, myocardial infarction
was recovered by ﬁbrinolytic drug and coronary angiogram did notier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Electrocardiogram on admission to emergency department. ST segment elevations in anterior derivations.
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cardiovascular risk factor except gender. The possible mechanism of
myocardial infarction in this patient can be hypercoagulation due to
the malignancy or chemotherapy regimens.
Venous thrombus in cancer patients is well known, but arterial
thrombus is rare and when occurs it can be life-threatening. Cancer
cells directly act on thrombin, causing blood coagulation and it isFig. 2. Normal coronary arteries on coronary angiography.enhanced through interactions between tumor cells and platelets; and
the coagulation capacity is enhanced through the enhancement of von
Willebrand factor and inﬂammatory cytokines.3 In testicular cancer,
tumor presence, high-position orchiectomy, and chemotherapy may
cause cardiovascular events, withal, that is associated with a decrease
in blood testosterone level.4 Many studies showed that myocardial
infarction is associated with anticancer drugs in testicular cancer5,6
and reports of drug-related myocardial infarction are increased in re-
cent years.7–10 Cisplatin is “the usual suspect” of chemotherapy related
myocardial infarction in testicular cancer. Shoji et al. reported a review,
which shows ten of thirteen patients with myocardial infarction, used
cisplatin including combined therapy.10 Nephrotoxicity is a consider-
able side effect of cisplatin, which may induce hypomagnesemia
through enhancement of the coagulation capacity and tubular distur-
bance related to the activation of platelets and vascular endothelial
cells, leading to coronary vasospasm.11 Hypomagnesemia occurs in
87% of testicular cancer patients treated with cisplatin.12 This may
persist for up to years after treatment, so hypomagnesemia caused cor-
onary events may occur in both early terms during chemotherapy and
years later. In our patient, magnesium level and coagulation markers
were not measured. Bleomycin is related to Raynaud's phenomenon
and pulmonary ﬁbrosis and etoposide are thought to the pathogenesis
of interstitial pneumonia. Coronary vasospasm is another possible
mechanism for chemotherapy related MI, but BEP drugs are not usually
responsible for it. 5-ﬂuorouracil is the most common agent associated
with coronary artery spasm.
YST is rare in young adults and there was not any literature data
about the togetherness of YST and chemotherapy related myocardial
infarction. Therewithal, thatwas theﬁrst reported casewhichwas treat-
ed with ﬁbrinolytic therapy. Normal coronary arteries and no plaque at
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hypercoagulation of possible mechanism of myocardial infarction in
our patient.
Although acute coronary events time varies in testicular cancer, they
approximately occur ten days after start of each chemotherapy course.13
The earliest literature report about myocardial infarction in testicular
cancerwas at the ﬁfth day of start of treatmentwith bleomycin, vinblas-
tine and cisplatin.14 Myocardial infarction developed on the fourth day
of the third chemotherapy course in our case. In a study with 48
patients, all of the three patients died from myocardial infarction had
a history of chest radiation therapy, so late myocardial infarction in
testicular cancer is concerned with radiotherapy.15
Today, the relationship between cisplatin and myocardial infarction
is well known. The testicular cancer patients are younger and usually do
not have cardiovascular risk factor. Therefore it is difﬁcult to predict the
myocardial infarction in these patients. When BEP protocol is planned,
physicians need to pay attention to some points. Patients should be
screened for cardiovascular disease and risk factors. Because it is a com-
mon health problem in young adults, smoking cessation andweight loss
in obese patients should be forced. High-risk patients can be performed
with cardiac imaging such as exercise ECG andmyocardial scintigraphy.
Patients should be given training about the symptoms of coronary
events. Magnesium level should be measured during chemotherapy
with cisplatin. Because the hypercoagulation is the most possible
cause of chemotherapy related myocardial infarction, oncologists
should consider anticoagulant treatment to the high-risk patients and
those with prior cardiovascular disease.
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